Send us a text In this episode, we discuss the 2025 MassBio Industry Snapshot — an annual report tracking employment trends, investment, real estate, and pipeline activity across the life sciences ecosystem. With talent displacement, funding cuts, and lab vacancies reshaping the landscape, the conversation zeroes in on how biopharma companies should rethink efficiency. Instead of defaulting to layoffs and budget slashing, Lawrence and Oscar explore how operational clarity, thoughtful pr...
All content for Lean By Design is the property of Oscar Gonzalez & Lawrence Wong and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Send us a text In this episode, we discuss the 2025 MassBio Industry Snapshot — an annual report tracking employment trends, investment, real estate, and pipeline activity across the life sciences ecosystem. With talent displacement, funding cuts, and lab vacancies reshaping the landscape, the conversation zeroes in on how biopharma companies should rethink efficiency. Instead of defaulting to layoffs and budget slashing, Lawrence and Oscar explore how operational clarity, thoughtful pr...
0117. Transformative Strategies for Scaling Operations in Biopharma
Lean By Design
19 minutes
1 year ago
0117. Transformative Strategies for Scaling Operations in Biopharma
Send us a text Ever wondered how to supercharge your company's operations without expanding your team? In this episode of Lean by Design, host Oscar Gonzalez reveals innovative strategies from a recent project with a dynamic 100-person company. Discover how you can enhance workflow efficiency by reimagining and optimizing your existing data and documentation. Explore actionable tips for transforming digital assets like PowerPoint slides and governance documents into powerful tools that drive ...
Lean By Design
Send us a text In this episode, we discuss the 2025 MassBio Industry Snapshot — an annual report tracking employment trends, investment, real estate, and pipeline activity across the life sciences ecosystem. With talent displacement, funding cuts, and lab vacancies reshaping the landscape, the conversation zeroes in on how biopharma companies should rethink efficiency. Instead of defaulting to layoffs and budget slashing, Lawrence and Oscar explore how operational clarity, thoughtful pr...
